Reply by authors (Changes in Use of Oral Androgen Pathway Directed Medications during the COVID-19 Era)

Author reply to editorials regarding the oral androgen pathway medications IQVIA paper

Reply by authors (Antegrade Instillation of UGN-101 [Mitomycin for Pyelocalyceal Solution] for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience)

Author reply to editorials regarding the antigrade UGN-101 initial experiences paper

SKOPE-Study of Ketorolac vs Opioid for Pain after Endoscopy: A Double-Blinded Randomized Control Trial in Patients Undergoing Ureteroscopy. Letter

We wrote a reply discussing the use of oral ketorolac. FDA labelling is for such use only as continuation therapy after parenteral administration. We argue that there is no reason for this.

Re: Delayed Radical Prostatectomy is Not Associated with Adverse Oncological Outcomes: Implications for Men Experiencing Surgical Delay Due to the COVID-19 Pandemic

We wrote a reply commenting on the statistical methods used.